AstraZeneca to divest US Synagis rights to Sobi
Transaction grants Sobi the right to participate in US profits and losses for MEDI8897 Upfront consideration of $1.5bn plus further contingent paymentsAstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction. Sobi will also have the right to participate in AstraZeneca’s share of US